title: [Determination of efficacy of second application of Urokinase Medac in a diabetic foot syndrome].
abstract: The results of treatment of 37 patients, suffering diabetes mellitus, were analyzed, in 16 of whom--for critical ischemia of the lower extremities (LE) and purulent-necrotic form of a diabetic foot syndrome 2 courses of treatment using urokinase were done together with pathogenetic and symptomatic therapy. Second introduction of Urokinase Medac was effective for reduction of a fibrinogen level, as well as for increase in a blood supply of a LE tissues, what have promoted a better healing of the wounds. Reduction of a fibrinogen level have had occurred faster, a trustworthy improvement of a state was observed from a 10th day of treatment during the first and the second course. Rising of the oxygen partial pressure in a LE tissues (TcPO2) was more durable, trustworthy--in 20 days while doing the first and second courses of treatment. The higher TcPO2 have lasted in 3-4 mo also. Positive dynamics of the wounds healing was noted also after commitment of the first course of treatment, a majority of ulcers having reduced in size. At the end of the second course of treatment a complete healing or an active epithelization of the wounds were observed in 14 patients. Reduction of the fibrinogen level was connected with achievement of the diabetes mellitus compensation state, with local treatment of ulcers, elimination of an acute purulent-necrotic process.
authors.forename: M B
authors.initials: MB
authors.lastname: Horobeĭko
mesh_terms: D001785:Blood Gas Monitoring, Transcutaneous; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000473:pathology; D017719:Diabetic Foot / Q000188:drug therapy* / Q000473:pathology; D004334:Drug Administration Schedule; D005340:Fibrinogen / Q000378:metabolism; D006801:Humans; D007511:Ischemia / Q000188:drug therapy* / Q000473:pathology; D007866:Leg / Q000473:pathology; D062326:Re-Epithelialization / Q000502:physiology*; D016896:Treatment Outcome; D014568:Urokinase-Type Plasminogen Activator / Q000378:metabolism / Q000627:therapeutic use*
chemical_list: D005340:Fibrinogen; D014568:Urokinase-Type Plasminogen Activator